<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Expression of prolactin and of prolactin and <z:chebi fb="0" ids="50114">estrogen</z:chebi> receptors in lymphocytes, bone marrow, and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines suggests that hormonal modulation may influence <z:hpo ids='HP_0002665'>lymphoma</z:hpo> risk </plain></SENT>
<SENT sid="1" pm="."><plain>Prolactin and <z:chebi fb="0" ids="50114">estrogen</z:chebi> promote the proliferation and survival of B cells, factors that may increase non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> risk, and effects of <z:chebi fb="0" ids="50114">estrogen</z:chebi> may be modified by <z:chebi fb="5" ids="18135">catechol</z:chebi>-O-methyltransferase (COMT), an enzyme that alters estrogenic activity </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="38559">Cytochrome P450</z:chebi> 17A1 (CYP17A1), a key enzyme in <z:chebi fb="0" ids="50114">estrogen</z:chebi> biosynthesis, has been associated with increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk and may affect <z:hpo ids='HP_0002665'>lymphoma</z:hpo> susceptibility </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the polymorphisms prolactin (PRL) -1149G&gt;T, CYP17A1 -34T&gt;C, and COMT 108/158Val&gt;Met, and predicted haplotypes among a subset of participants (n = 308 cases, n = 684 controls) in a San Francisco Bay Area population-based non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> study (n = 1,593 cases, n = 2,515 controls) conducted from 1988 to 1995 </plain></SENT>
<SENT sid="4" pm="."><plain>Oral contraceptive and other hormone use also was analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>Odds ratios (OR) for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were reduced for carriers of the PRL -1149TT genotype [OR, 0.64; 95% confidence interval (95% CI), 0.41-1.0; OR, 0.53; 95% CI, 0.26-1.0, respectively] </plain></SENT>
<SENT sid="6" pm="."><plain>Diffuse large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> risk was increased for those with CYP17A1 polymorphisms including CYP17A1 -34CC (OR, 2.0; 95% CI, 1.1-3.5) </plain></SENT>
<SENT sid="7" pm="."><plain>ORs for <z:hpo ids='HP_0000001'>all</z:hpo> non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> among women were decreased for COMT IVS1 701A&gt;G [rs737865; variant allele: OR, 0.53; 95% CI, 0.34-0.82; OR, 0.42; 95% CI, 0.23-0.78, respectively] </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with never users of oral contraceptives, a 35% reduced risk was observed among oral contraceptive users in the total population </plain></SENT>
<SENT sid="9" pm="."><plain>Reduced ORs for <z:hpo ids='HP_0000001'>all</z:hpo> non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were observed with use of exogenous <z:chebi fb="1" ids="50114">estrogens</z:chebi> among genotyped women although 95% CIs included unity </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that PRL, CYP17A1, and COMT may be relevant genetic loci for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and indicate a possible role for prolactin and <z:chebi fb="0" ids="50114">estrogen</z:chebi> in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> pathogenesis </plain></SENT>
</text></document>